Inventor

POMPER MARTIN G

US52 patents

⚠️ This page may combine multiple inventors who share the name “POMPER MARTIN G”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

POMPER MARTIN G

UNIV JOHNS HOPKINS

PSMA-binding agents and uses thereof

PSMA-targeting compounds and uses thereof

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

PSMA-binding agents and uses thereof

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

PSMA-binding agents and uses thereof

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

PSMA-targeting compounds and uses thereof

PSMA targeted fluorescent agents for image guided surgery

Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy

68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents

Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof

Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

Compositions and methods for chemical exchange saturation transfer (CEST) based magnetic resonance imaging (MRI)

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer

Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL

Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy

Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use

PSMA-binding agents and uses thereof

PSMA targeted fluorescent agents for image guided surgery

Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy

PSMA targeted fluorescent agents for image guided surgery

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)

Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)

Compositions of nucleic acid-containing nanoparticles for in vivo delivery

Compositions and methods for treating pancreatitis and pain with death receptor agonists

Ameliorating systemic sclerosis with death receptor agonists

Glucose conjugates of triptolide, analogs and uses thereof

PSMA-based molecular-genetic reporter system

Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)

Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy

PSMA-based molecular-genetic reporter system

PEG-Prom mediated surface expression of avidin/streptavidin

PAMAM dendrimer based CEST imaging agents and uses thereof

Red fluorescent aldehyde dehydrogenase (ALDH) substrate

TSPO-targeting compounds and uses thereof

18F-FNDP for pet imaging of soluble epoxide hydrolase (sEH)

POMPER MARTIN G

Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents

Imaging infection with compounds that bind to thymidine kinase

Imaging infection with compounds that bind to thymidine kinase

CHANDRAN SACHIN S

Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer

UNIV COLORADO REGENTS

Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging

UNIV VIRGINIA COMMONWEALTH

Tripartite cancer theranostic nucleic acid constructs